pubmed-article:8230543 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0005684 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0039593 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0312418 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0036667 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0247342 | lld:lifeskim |
pubmed-article:8230543 | lifeskim:mentions | umls-concept:C0598148 | lld:lifeskim |
pubmed-article:8230543 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:8230543 | pubmed:dateCreated | 1993-12-10 | lld:pubmed |
pubmed-article:8230543 | pubmed:abstractText | TP-40 is a hybrid fusion protein produced by recombinant technology and consists of a molecule of transforming growth factor-alpha (TGF-alpha) fused to the Pseudomonas exotoxin PE-40. A panel of human and murine bladder cancer cell lines was found to be universally sensitive in vitro to TP-40 in a clonogenic assay. All lines expressed receptor for epidermal growth factor (EGF), though none demonstrated gene amplification for the EGF receptor. The sensitivity to TP-40 may be blocked by preexposure to EGF. Six human bladder tumors taken directly from patients were all sensitive in vitro to TP-40; these included well-differentiated tumors. TP-40 may prove to be effective as an intravesical agent in bladder cancer via selective targeting to cells that express EGF receptors, as do the majority of human bladder cancers. | lld:pubmed |
pubmed-article:8230543 | pubmed:language | eng | lld:pubmed |
pubmed-article:8230543 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8230543 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8230543 | pubmed:month | Dec | lld:pubmed |
pubmed-article:8230543 | pubmed:issn | 0022-5347 | lld:pubmed |
pubmed-article:8230543 | pubmed:author | pubmed-author:von HoffD DDD | lld:pubmed |
pubmed-article:8230543 | pubmed:author | pubmed-author:YeeDD | lld:pubmed |
pubmed-article:8230543 | pubmed:author | pubmed-author:SarosdyM FMF | lld:pubmed |
pubmed-article:8230543 | pubmed:author | pubmed-author:HutzlerD HDH | lld:pubmed |
pubmed-article:8230543 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8230543 | pubmed:volume | 150 | lld:pubmed |
pubmed-article:8230543 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8230543 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8230543 | pubmed:pagination | 1950-5 | lld:pubmed |
pubmed-article:8230543 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:meshHeading | pubmed-meshheading:8230543-... | lld:pubmed |
pubmed-article:8230543 | pubmed:year | 1993 | lld:pubmed |
pubmed-article:8230543 | pubmed:articleTitle | In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. | lld:pubmed |
pubmed-article:8230543 | pubmed:affiliation | Division of Urology and Oncology, University of Texas Health Science Center, San Antonio 78284-7845. | lld:pubmed |
pubmed-article:8230543 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8230543 | pubmed:publicationType | In Vitro | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8230543 | lld:pubmed |